Analysis of Weight Loss and Lipid-lowering Adverse Events in Chronic Hepatitis B Patients treated with Tenofovir Disoproxil Fumarate : Using Korea adverse event reporting system database and U.S. Food and Drug Administration adverse event reporting system database

• 발행기관: 대한약학회
• 저자명: Ju Young Kim Hae Sun Suh
• 간행물 정보: 『약학회지』제68권 제5호(2024년), 362~370쪽, 전체 9쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2024.10.31

국문 초록

Chronic hepatitis B, primarily caused by the Hepatitis B virus, is prevalent in Korea and significantly contributes to liver cancer. Tenofovir disoproxil fumarate (TDF), a key treatment for hepatitis B, is preferred for its efficacy and low resistance. Recently, potential positive side effects, such as weight loss and lipid-lowering, have been contentious, especially since weight gain and high lipid levels are known to influence liver cancer. This study aimed to assess the association between TDF use and adverse events of weight loss and lipid-lowering in chronic hepatitis B patients using data from the Korean Adverse Event Reporting System (KAERS) and the US FDA Adverse Event Reporting System (FAERS) from 2013 to 2022. Disproportionality analysis was conducted on patients reporting adverse events after nucleotide analogues. Despite examining 6,688 reports (11,245 drug-adverse event pairs) from KAERS and 35,656 reports (126,060 drug-adverse event pairs) from FAERS, no significant weight loss or lipid-lowering signals were found. The findings suggest TDF may not be linked to these adverse events, though ongoing monitoring and cautious interpretation are advised, as the study does not establish causality.

목차

Introduction

Methods

Results

Discussion

Conclusion

Acknowledgment

Conflict of Interest

References

키워드

Chronic hepatitis B Tenofovir Disoproxil Fumarate Adverse events KAERS DB FAERS DB